Praxair Says Recent Ruling Won't 'Devastate' Medical Patents
Urging the full Federal Circuit on Thursday to deny Mallinckrodt's petition for rehearing of a panel decision upholding the invalidity of five patents covering its respiratory drug Inomax, Praxair Inc. said...To view the full article, register now.
Already a subscriber? Click here to view full article